Şunu aradınız:: metform (Letonca - İngilizce)

metform nu un
sitagliptin with

sitaglipt ns ar metform nu un
sitagliptin with

4 mg rosiglitazona un 1000 mg metform na hidrohlor da).
4 mg rosiglitazone and 1,000 mg metformin hydrochloride).

sitaglipt ns 50 mg + metform ns 1000 mg (n=178)
sitagliptin 50 mg + metformin 1000 mg (n=178)

lietojot kombin cij ar metform nu, novomix 70 deva ir j piel go.
when novomix 70 is used in combination with metformin the dosage should be adjusted.

2 mg rosiglitazona un 500 mg metform na hidrohlor da; s rt kr s:
2 mg rosiglitazone and 500 mg metformin hydrochloride; pink:

metform na vai pparγ agonista deva ir j saglab, un sitaglipt ns j lieto vienlaikus.
the dosage of metformin or pparγ agonist should be maintained, and sitagliptin administered concomitantly.

rosiglitazona devu ir iesp jams lietot kop ar metform nu un var kori t, pirms pacientam ordin avandamet.
the dose of rosiglitazone may be added to metformin and adjusted before a patient is switched to avandamet.

avandamet lietošana dienreizes laik vai tieši p c šanas var samazin t metform na rad tos ku a trauc jumus.
taking avandamet with or just after food may reduce any stomach problems caused by metformin.

dažiem pacientiem, uzs kot kombin tu terapiju ar sitaglipt nu un metform nu, rad s diskomforta saj ta v der.
some patients have experienced stomach discomfort when starting the combination of sitagliptin and metformin together.

ja slimnieks jau sa em tr sk rt ju terapiju, avandamet devai j nodrošina t das pašas rosiglitazona un metform na devas k agr k.
if the patient is already using triple therapy, then avandamet is given to provide the same doses of rosiglitazone and metformin as before.

2. tipa diab ta pacientiem novomix 50 var lietot monoterapij vai kombin cij ar metform nu, ja glikozes l me a asin s kontrole ir nepietiekama lietojot tikai metform nu.
in patients with type 2 diabetes, novomix 50 can be given in monotherapy or in combination with metformin, when the blood glucose is inadequately controlled with metformin alone.

rezult tus, kas ieg ti, lietojot avandia kop ar metform nu k atseviš as tabletes, izmantoja, lai pamatotu avandamet lietošanu tai pašai indik cijai.
the studies of avandia taken with metformin as separate tablets were used to support the use of avandamet in the same indication.

kl niskos p t jumos, lietojot tesavel monoterapijas veid un sitaglipt nu k kombin tas terapijas da u kop ar metform nu vai pioglitazonu, sitaglipt na lietot jiem nov rotais hipoglik mijas biežums bija l dz gs k placebo lietot jiem.
in clinical trials of tesavel as monotherapy and sitagliptin as part of combination therapy with metformin or pioglitazone, rates of hypoglycaemia reported with sitagliptin were similar to rates in patients taking placebo.

dažiem pacientiem, kombin jot tesavel ar sulfonilur nvielas atvasin jumu un metform nu, rad s š das blakuspar d bas: oti bieži: zems cukura l menis asin s.
some patients have experienced the following side effects while taking tesavel in combination with a sulphonylurea and metformin:

3 metform ns: lietojot vienlaikus vair kas 1000 mg metform na devas divreiz dien kop ar 50 mg sitaglipt na, pacientiem ar 2. tipa cukura diab tu noz m gas sitaglipt na farmakokin tikas p rmai as nekonstat ja.
co-administration of multiple twice-daily doses of 1000 mg metformin with 50 mg sitagliptin did not meaningfully alter the pharmacokinetics of sitagliptin in patients with type 2 diabetes.

tika veikts ar p t jums, kur sal dzin ja, k ds iedarb gums ir rosiglitazona, bet k di – placebo (fikt va rst šana) pievienošanai metform nam.
another study was also carried out comparing the effects of adding either rosiglitazone or placebo (a dummy treatment) to metformin.

20 kombin t s terapijas p t jums pievienojot sitaglipt nu - 0, 7 ‡ 100 mg reizi dien metform na terapijai (n=453) pievienojot sitaglipt nu 100 mg reizi dien
placebo-corrected mean